



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref No: SPL/Corp.Sec/2024-25/199

Dated:13.06.2024

To,
Department of Corporate Services
Bombay Stock Exchange Limited,
Phirojshah Jeejobhoy tower,
Dalal Street,
Mumbai-400001.

Sub: Clarification on Non-Disclosure of reasons for delay in submission of financial results for Period/Year ended March 31, 2024 vide your email dated 12th June 2024.

Ref:Our Letter dated 30th May 2024 Outcome of the Board Meeting with Ref No:SPL/CORP-SEC/2024-25/BSE/187 and Regulation 30 Disclosure with Ref No: SPL/CORP-SEC/2024-25/BSE/187 filed on BSE Portal.

ScripCode:524703

Respected Sir

This is to bring to your kind notice that the as per the SEBI (LODR) Regulations, under Regulation 33, the company is required to submit to the stock exchanges its annual audited standalone and consolidated financial results along with the audit report for the financial year ended March 31, 2024 within sixty days of the end of the financial year i.e. May 30, 2024.

However, in terms of above cited SEBI Circular No. CIR/CFD/CMD-1/142/2018 dated November 19, 2018, the Company would like to inform that we have informed the exchange vide Outcome of the Board Meeting and Disclosure under Regulation 30 the below mentioned reason for delay in Filing of Audited and Consolidated Financials for the Quarter and Year ended 31st March 2024.We Would like to reproduce the reason again in detail to ensure compliance with provision of Regulation 33 of SEBI Circular No. CIR/CFD/CMD-1/142/2018 dated November 19, 2018.

- A) Shri. Rakesh Parekh had resigned from the Post of Chief Financial Officer with effect from 31st December 2023.Find enclosed herewith copy of the Intimation submitted to exchange on 22nd November 2023 (**Annexure A**).
- B) Shri. Vijay Kajrekar assumed Office as Chief Financial Officer on 30th March 2024, despite of the Best efforts put in for finalisation of accounts by the Management Accounts were not ready due to which it was not adopted /approved at the Board Meeting (**Annexure B**).
- C) Outcome of the Board Meeting /Regulation 30 Upload which contains reasons for Non submission of Audited Financials on 30th May 2024 submitted on 30th May 2024 (**Annexure C**).
- D) Further we would like to inform you that Company vide its Board Meeting held on 05th June 2024 has already approved Audited and Consolidated Financials and



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

submitted the same as per Regulation 33 of SEBI (LODR) with Exchange in pdf and XBRL Mode.

In view of the above clarification we request you to kindly note that we have always adhered to the statutory timelines in the past and therefore request you to kindly consider the clarification given and consider that Company has done compliance with respect to Disclosure of reasons for delay in submission of financial results for Period/Year ended March 31, 2024.

Thanking you,
Yours Faithfully,
FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray
Company Secretary

Encl:

1. Intimation about Resignation of Shri. Rakesh Parekh as Chief Financial Officer.
2. Intimation about Appointment of Shri. Vijay Kajarekar as Chief Financial Officer.
3. Outcome of the Board Meeting/Disclosure under Regulation 30 of SEBI (LODR) Regulation 2015.



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



ANNEXURE A



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

8Ref:SPL/BSE/CORP.SEC/2023-24/118

Dated:22.11.2023

To,
Department of Corporate Services
Bombay Stock Exchange Limited,
PhirojshahJeejobhoy tower,
Dalal Street,
Mumbai-400001.

Sub: Intimation of Resignation of Chief Financial Officer as per Regulation 30 of the SEBI (LODR) Regulation 2015.

ScripCode: 524703

Respected Sir

With reference to the captioned subject and in compliance with Regulation 30 read with Para A of Part A of Schedule III of the SEBI (LODR) Regulations 2015, this is to inform you that Mr Rakesh Parekh has tendered his resignation from the Post of Chief Financial Officer (CFO) and KMP of the Company w.e.f. 31st December 2023 (after the closing of business hours) on account of personal reasons.

Further ,Mr Rakesh PParekh has also confirmed that there is no other material reason other than mentioned in his resignation letter(Attached resignation letter).

The details required under Regulation 30 of the SEBI (LODR) Regulation 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9,2015 are given in the enclosed Annexure I.

The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchange in due course.

You are requested to kindly take note of the same and take it on record.

Thanking you, -



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Yours Faithfully,
FOR SANDU PHARMACEUTICALS LTD.

PRATIKA
PRATHAMESH
MHAMBRAY

Digitally signed by
PRATIKA PRATHAMESH
MHAMBRAY
Date: 2023.11.22
14:53:16 +05'30'

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001567

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Annexure I

The details required to be furnished under Regulation 30 of the SEBI(LODR) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9,2015 issued hereunder is furnished below:

Name	Mr Rakesh Parekh
Reason for change Viz appointment, Resignation, removal, death or otherwise	As mentioned in the Resignation letter, Resignation due to personal reasons
Date of cessation	31 st December 2023
Brief profile (incase of appointment)	Not Applicable
Disclosure of relationship between Directors (incase of appointment)	Not Applicable



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



From
Mr Rakesh Parekh
E/319-A-1 Apartments, Dhanukarwadi Shivaji Road,
Kandevali West, Mumbai 400067

Dated: 22.11.2023

To,
The Board of Directors
Sandu Pharmaceuticals Limited
Plot No 25,26 29& 30
Pilerne Industrial Estate, Marra,
Saligao, Bardez Goa

Subject: Resignation from the post of Chief Financial Officer.

Dear Sir,


I am submitting my resignation, from the Post of CFO of Sandu Pharmaceuticals Limited due to personal reason i.e for furtherance of my professional carrier.


Kindly consider the same and relieve me of my duties w.e.f 31st December 2023.

I further confirm that there are no other material reasons other than provided above.

I take this opportunity to express my sincere Gratitude for the co-operation and support extended to me during my tenure as CFO of the Company. It was a good learning experience with the Senior Consultants, CAs during my tenure with Sandu Pharmaceuticals Limited.

Thanking you
Yours Faithfully


Rakesh Parekh
PAN:AMYPP0706G


SANDU PHARMACEUTICALS LTD
P. B NO. 17201, SANDU NAGAR
D K SANDU MARG,
CHEMBUR, MUMBAI - 400 071



ANNEXURE B SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2023-24/BSE/173

Dated:30.03.2024

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Saturday, 30th March 2024 at 06:00 p.m. and concluded at 6:35 p.m. discussed the following business: -

1. Considered and Appointed CA Shri Balram Viswanathan (DIN: 10245195) Non Executive Independent Director, as Chairman of the Board. The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed Annexure I
2. Considered and Appointed Shri Vijay Kajrekar as Chief Financial Officer of the Company (CFO). The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as is enclosed Annexure I
3. Considered and took note of the below mentioned Retiring Non Executive Independent Director after completion of 02nd terms of 05 years tenure at closure of Business hour i.e 31st March 2024. The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as is enclosed Annexure I
 - A. Shri K Vinay Kumar (DIN:02322747)
 - B. Shri Dilip Salgaocar (DIN:00044240)
 - C. Shri Dr Madan Kapre (DIN:03113515)
 - D. Shri Dr Krishna Deshpande (DIN:06557518)
4. Considered and Appointed M/S Akhil Pai & Co, And M/S Uday & Uday Associates Chartered Accountant As The Internal Auditor For t he Goa Plant And Mumbai Corporate Office For The Financial Year 2024-25. The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN: L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as is enclosed Annexure I

5. Considered and approved Reconstitution of Audit Committee, Nomination and Remuneration Committee and Stakeholder Relationship Committee.

a) Audit Committee

Sr No	Names of Directors	Category
1	CA Shri Balram Viswanathan	Non Executive Independent Director
2	Shri Adv Ajit Kantak	Non Executive Independent Director
3	Shri Umesh B Sandu	Executive Director

b) Nomination and Remuneration Committee

Sr No	Names of Directors	Category
1.	Adv Shri Ajit Kantak	Non Executive Independent Director
2.	CA Shri Balram Viswanathan	Non Executive Independent Director
3	Shri Shashank B Sandu	Non Executive Director

c) Stakeholders Relationship Committee

Sr No	Names of the Category	Category
1	Shashank B Sandu	Non Executive Director
2	Ajit Kantak	Non Executive Independent Director
3	Umesh B Sandu	Executive Director

You are requested to kindly take the same on record.

Yours Faithfully,



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

FOR SANDU PHARMACEUTICALS LTD.

PRATIKA Digitally signed
by PRATIKA
PRATHAME PRATHAMESH
SH MHAMBRAY
MHAMBRAY Date: 2024.03.30
18:41:56 +05'30'

Pratika Mhambray
Company Secretary



ISO 9001:2015 CERTIFIED ORGANISATION

AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1905PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Annexure-I

Details of disclosure as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr.No	Details of events that need to be provided	Information of such event(s)	
		1. CA Shri Balram Viswanathan (DIN: 10245195)	2. Shri Vijay Kajrekar
1	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Appointment as Non Executive Chairman of the Board	Appointment as Chief Financial Officer of the Company
2	Date of appointment/ Cessation and terms of appointment;	30 th March 2024	30 th March 2024
3	Brief Profile (in case of appointment);	<p>He is BCOM, FCA, CPA(USA) and has expertise in Audit, Tax, M&A Advisory, Due Diligence, Compliance and Valuation services along with financial control, planning & analysis, regulatory reporting, business strategy, treasury and risk management experience gained in large International Banks.</p> <p>He has previously worked in senior roles viz. CFO International Banking Group at National Bank of Kuwait, Chief Finance and Operating officer at Gulf Finance Dubai, UAE, Country Head of Finance at Al Ahli Bank of Kuwait in Dubai, UAE, Vice President Financial reporting and Group Risk control at Deutsche Bank in India and as a Senior Auditor at Ernst & Young in India. .</p>	<p>Shri Vijay Kajrekar is Having 30 years of experience in various capacities of Finance, Taxation & Loan Syndication.</p> <p>he is has worked as</p> <ol style="list-style-type: none">1. Manager Finance - Goa Institute of Management.2. Manager Finance - A.W. Faber Castell (India) Pvt. Ltd.3. Manager Accounts & Finance - Goa Resistors Pvt. Ltd.4. Sr. Manager Commercial - Goa Institute Industries Pvt. Ltd.



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

		<p>He has a vast and varied experience having engaged in audit of clients in manufacturing, trading, health, Hotels and food & beverages, real estate, contracting and construction companies, oil and gas, holding companies, telecommunications, banking and other sectors.</p> <p>Having dealt with regulators across the GCC, Federal Reserve, FSA and MAS, he is well experienced in the areas of Corporate Governance and Risk Management, International Auditing Standards (IAS's</p>	
4	Disclosure of relationships between directors. (in case of Appointment)	Not Applicable	Not Applicable

Sr No	Details of events that need to be provided	Information of such event(s)	
		3. Shri K Vinay Kumar (DIN:02322747)	4. Shri Dilip Salgaocar (DIN:00044240)
1	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Retirement due to Completion of Tenure as an Independent Director	Retirement due to Completion of Tenure as an Independent Director
2	Date of appointment/ Cessation and terms of appointment;	<p>Completion of 2nd term Tenure as an Independent Director with effect from end of day on 31st March 2024.</p> <p>Terms of Appointment: Not Applicable</p>	<p>Completion of 2nd term Tenure as an Independent Director with effect from end of day on 31st March 2024.</p> <p>Terms of Appointment: Not Applicable</p>
3	Brief Profile (in case of appointment);	Not Applicable	Not Applicable



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

4	Disclosure of relationships between directors. (in case of Appointment)	Not Applicable	Not Applicable
----------	---	----------------	----------------

Sr No	Details of events that need to be provided	Information of such event(s)	
		5. DR Shri Madan Kapre (DIN:03113515)	6. Shri Dr Krishna Deshpande (DIN:06557518)
1	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Retirement due to Completion of Tenure as an Independent Director	Retirement due to Completion of Tenure as an Independent Director
2	Date of appointment/ Cessation and terms of appointment;	Completion of 2 nd term Tenure as an Independent Director with effect from end of day on 31 st March 2024. Terms of Appointment: Not Applicable	Completion of 2 nd term Tenure as an Independent Director with effect from end of day on 31 st March 2024. Terms of Appointment: Not Applicable
3	Brief Profile (in case of appointment);	Not Applicable	Not Applicable
4	Disclosure of relationships between directors. (in case of Appointment)	Not Applicable	Not Applicable

Sr No	Details of events that need to be provided	Information of such event(s)	
		7. M/S Akhil Pai & Co	8. M/S Uday & Uday Associates
1	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Considering the term of expiry of internal auditor, CA akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2024-2025	Considering the term of expiry of internal auditor, CA akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2024-2025
2	Date of appointment/ Cessation and terms of appointment;	01.04.2024	01.04.2024
3	Brief Profile (in case of	He is Practising Chartered	<u>Practicing chartered Accountant</u>



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Coa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

	appointment);	Account . conducted Tax Audits of Proprietorship Concerns, Firms and Companies,We also look into other Companies law matters, Income Tax related & GST matters.	<u>firm specialized in Companies Audit ,Cooperative Sector Audit ,Nationalized Bank Audit and other</u>
4	Disclosure of relationships between directors. (in case of Appointment)	Not Applicable	Not Applicable

FOR SANDU PHARMACEUTICALS LTD.

PRATIKA Digitally signed by
PRATHAMESH PRATIKA
H PRATHAMESH
MHAMBRAY MHAMBRAY
 Date: 2024.03.30
 18:42:21 +05'30'

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





ANNEXURE C
SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2024-25/BSE/187

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Dated:30.05.2024

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Thursday, 30th May 2024 at 05:00 p.m. and concluded at 10.40 p.m. discussed the following business: -

1. Re-Appointment of, CMA Shekhar Joshi & Co Cost Accountants, having firm Registration No. 100448 as the Cost Auditors of the Company for the financial year 2024-25.
2. Considered and approved sale of 100% investments in Sandu Phytoceuticals Private Limited ,Wholly owned Subsidiary of Sandu Pharmaceuticals Limited. Shares to be sold to Shri Umesh Sandu Promoter of Sandu Pharmaceuticals Limited and Shri Shashank Sandu Promoter of Sandu Pharmaceuticals Limited for consideration amount of Rs 66700/- (Sixty Six Thousand Seven Hundered only) as per the valuation Report issued by CA Murli Chandak, IBBI Registered valuer of Securities and financial assets dated 28TH May 2024.

Further we would like to inform that Standalone and Consolidated Financials for Quarter and Year ended 31st March 2024 could not be uploaded as Chief Financial Officer Shri Vijay Kajrekar was appointed only on 30th March 2024 as required under regulation 33 of SEBI(listing Obligation and Disclosure Requirement)Regulation 2015.

Further, in this connection and in continuation of our letter dated 16.03.2024 the Trading Window for dealing in the equity shares of the Company had been closed from 01st April 2024 and will continue to remain closed till 48 hours after the date of declaration of audited Financial Results for the quarter / year ended 31st March 2024, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code for prohibition of Insider Trading.The date of the Board Meeting for the aforesaid purpose i.e Finalisation of Financials shall be intimated separately after finalizing the same.

Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A and Annexure B.



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Coa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

You are requested to kindly take the same on record.

Yours Faithfully,

FOR SANDU PHARMACEUTICALS LTD.

PRATIKA
PRATHAMESH
MHAMBRAY
MHAMBRAY

Digitally signed by
PRATIKA PRATHAMESH
MHAMBRAY
Date: 2024.05.30
22:39:18 +05'30'

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Annexure A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023

Sr No	Particulars	Cost Auditor
1.	Reason for change viz. appointment, resignation, removal death or otherwise	Shekhar Joshi & Co Reappointment
2.	Date of appointment/cessation (as applicable)& term of appointment	Date of Reappointment 30.05.2024 Term of appointment: Financial Year 2024-25
3.	Brief Profile (incase of appointment)	Shekhar Joshi is M.Com, LL.B, FCMA, M.B.A. with 35 plus years of experience.He is Visiting Faculty at The ICFAI Business School, Sterling Institute of Management, The Atharva Institute of Management Studies, Finplan Institute and Institute of Cost Accountants of India Areas of Specialization Cost Audit• Management Consultancy• Statutory Compliances• Business Valuation for Banking and Take Over• Assisting Mergers and Acquisitions• Due Diligence• Project Appraisal and Evaluation• Internal and MIS systems• Stock Audits• Product Costing• Market Profitability Analysis. Projects Handled Cost Audit and Cost Compliances• Implementation of Costing Systems• Due Diligence• Feasibility study of Merger• Corporate Valuations• MIS Implementation• Costing MIS and Routine Assistance• Budgets and Follow ups

Annexure B

Sr No	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associates company of the listed entity during the last financial year	Turnover of Sandu Phytoceuticals Private Limited as on 31 st March 2023 is Rs 0 constituting 0 % to consolidated income. Net Worth as on 31 March 2023 is INR 72725 constituting 0.00 % to Net Worth
b)	Date on which the agreement for sale has been entered into	NA
c)	The expected date of completion of sale/disposal	The sale will be concluded once the transfer of shares is approved by the Board of Directors of Sandu Phytoceuticals Private Limited and shares are transferred from Sandu Pharmaceuticals Limited to Shri Umesh Sandu (50%) and Shri Shashank Sandu (50%) vide share transfer form.



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

		The total consideration amount payable for Transfer of Shares will be Rs 66700/-
d)	Consideration received from such sale/disposal	<p>The Company has no revenues for the last year and only has costs in its Profit and Loss and therefore incurring losses. Sandu Phytoceuticals has no plans to add any activity to this company and to reduce all administrative and related costs, the company's shareholding is being sold. We have obtained a valuation from an authorized registered valuer and the Board Approval has been taken on 30th May 2024. The Consideration of the shares is fixed at .Rs 66700/-</p> <p>The consideration Amount of Rs 33350 will be paid by Shri Umesh Sandu and Rs 33350 will be paid by Shri Shashank Sandu.</p>
e)	Brief details of buyers and whether any of the buyer belong to the Promoter/Promoter Group companies. If yes details thereof	<p>Shri Umesh Sandu and Shri Shashank Sandu.</p> <p>Shri. Umesh Sandu(DIN:01132141) is Managing Director and Promoter in Sandu Pharmaceuticals Limited holding 13,88,693 Equity Shares.</p> <p>Shri. Shashank Sandu (DIN: 00678098) is Non Executive Director and Promoter in Sandu Pharmaceuticals Limited holding 13,68,755 Equity Shares.</p> <p>Yes They Belong to Promoter Group</p>
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm length"	<p>Yes The Transactions with Shri Umesh B Sandu and Shri Shashank B Sandu is falling under related party transaction and is on arm length Basis</p> <p>However, the sale price will be the same as being sold to a "non related party"</p>
g)	Whether the sale, lease or disposal of the undertaking is outside scheme of arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulation.	NA
h)	Additionally , in case of a slump sale, indicative disclosure provided for amalgamation/merger, shall be disclosed by the Listed entity with respect to such slump sale	NA

AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1005PLG001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Coa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

FOR SANDU PHARMACEUTICALS LTD.

PRATIKA
PRATHAMESH
MHAMBRAY

Digitally signed by
PRATIKA PRATHAMESH
MHAMBRAY
Date: 2024.05.30
22:39:39 +05'30'

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in

